Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Wuhan City, China Clinical Trials

A listing of Wuhan City, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

This is a multicenter, randomized, openlabel, activecontrolled, parallel, phase III study which aims to assess the efficacy and safety of ferric citrate capsules for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis. This study is consisting of a Screening/Washout period (14 days) and a Treatment/Observation period ...

Phase

0.0 miles

Learn More »

The Early Diagnosis of Pulmonary Nodule Based on Multi-dimension Messages

By recruiting people with pulmonary nodules identified by CT scans, three groups are confirmed as the lung cancer group, the benign lung nodule group who are identified by pathological analysis, and the small lung nodule group that should be followed up. Then the serum, the urine and the clinical characteristics ...

Phase N/A

0.03 miles

Learn More »

The Value of PET Quantitative Analysis of Coronary Physiology in Coronary Microvascular Disease

With the aging of the population and the acceleration of urbanization process, the number of cardiovascular diseases in China continues to increase, with one in five adults suffering from cardiovascular disease. The mortality rate of cardiovascular disease in China is also on the rise, and cardiovascular disease deaths are now ...

Phase N/A

1.94 miles

Learn More »

Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies

Chimeric antigen receptor (CAR)-modified T cells (CAR-T cells) have the capabilities to recognize tumor associated antigen and kill tumor cells specifically. CAR-T therapy showed great effect on patients with relapsed or refractory B-cell malignancies. CAR consists of single chain variable fragment (scFv) and activation domain of T cell. In preclinical ...

Phase

1.94 miles

Learn More »

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Chimeric antigen receptor (CAR)-modified T cells (CAR-T cells) have the capabilities to recognize tumor associated antigen and kill tumor cells specifically. CD30 is originally described as a marker of Hodgkin's and R-S cells in Hodgkin's lymphoma. CD30 antibody has been applied to treat lymphocyte derived malignancies. To explore the potency ...

Phase

1.94 miles

Learn More »

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.

Phase

1.94 miles

Learn More »

Standardization and Optimization of TMS Protocols for the Treatment of PD With Depression or Cognitive Impairment

Transcranial magnetic stimulation(TMS) is a valuable non-invasive brain stimulation tool for interventional neurophysiology applications, which generate local current and modulates brain activity in a specific, cortico-subcortical network. Repetitive TMS (rTMS) is developed as it is safe and well-tolerated. The left dorsolateral prefrontal cortex (DLPFC) high-frequency rTMS treatment has been proved ...

Phase N/A

1.94 miles

Learn More »

Safety and Efficacy of Anti-CD123 CAR-T Therapy in Patients With Refractory/ Relapsed CD123+ Acute Myeloid Leukemia.

CD123 is a transmembrane subunit of the IL-3 receptor expressed on AML blasts. The investigators have conducted a third generationCD123-targeted CAR containing CD137 and CD28 costimulatory domains.This study aims to evaluate the safety and efficacy of anti-CD123 CAR-T cells in patients with relapsed/refractory CD123+ Acute Myeloid Leukemia.

Phase

1.94 miles

Learn More »

Safety and Efficiency Study of ET019003-T Cells in Relapsed Refractory CD19+ B Cell Leukemia and Lymphoma

ET019003-T cells is a human anti-CD19 CAR-T cells by fusing the anti-CD19 antibody Fab domain with the transmembrane and intracellular domains from the TCR, which can avoid mispairing with the T cell's endogenous TCR chains. Meanwhile, an independent ET190L1-CSR (Chimeric Signaling Receptor) is added to ET019003-T cells in trans, which ...

Phase

1.94 miles

Learn More »

Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas

A Phase II, open-label randomized, multicenter trial to compare nab-paclitaxel in combination with gemcitabine verus S1 with gemcitabine with respect to overall survival, objective tumor response rate and Progression Free Survival (PFS) in patients diagnosed with locally advanced or metastatic adenocarcinoma of the pancreas.

Phase

1.94 miles

Learn More »